(CANCER HEMATOPOIESIS AND IMMUNOLOGY) The mission of Cancer Hematopoiesis and Immunology (CHI) Program is hewed to the tenet of collaborative transdisciplinary research that is aligned with the UMCCC strategic research priorities. Members of the CHI Program are committed to the pursuit of research that defines the fundamental roles of immune and non- immune hematopoietic cells in cancer as well as post-transplantation therapies. Working under the broad theme of cellular and innate immunity, normal and malignant hematopoiesis, and hematopoietic stem cell transplantation biology, the CHI Program seeks to develop translational approaches that will improve hematopoietic cell transplantation (HCT) outcomes and hasten the development of novel vaccination strategies. Toward these goals, the CHI Program is a diverse, interdisciplinary research group comprised of 24 members from 10 departments within three University of Michigan schools/colleges. The CHI Program has $10.3M in annual direct funding (88% peer-reviewed), with $2.7M from the NCI, $5.3M from other NIH sources and $2.3M in additional support. During the past project period, the Program generated 376 publications, including high impact reports appearing in Cell, Nature, Science, NEJM, and the JCI. The CHI Program enjoys strong interactions with other UMCCC members, underlined by 24% of their publications arising from intra- programmatic efforts and 43% from inter-programmatic collaborations. To build on these advances, Program aims include: 1) elucidate molecular mechanisms regulating normal immune/non-immune hematopoietic cell function during homeostasis and their alterations in cancer and HCT, 2) characterize the role of the tissue microenvironment in controlling the function and regulation of immune cells in cancer, hematopoiesis and HCT and 3) define key concepts, approaches, and reagents in preclinical studies to translate the most compelling advances into the clinic via collaboration with the Translational and Clinical Research (TACR) Program. As such, CHI Program members support the UMCCC mission by performing state-of-the-art research underlying both major and less common cancer types within our catchment area, while training the next generation of cancer researchers, and promoting collaboration with other UMCCC Programs and beyond.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-31
Application #
9993329
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
31
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Khoriaty, Rami; Hesketh, Geoffrey G; Bernard, Amélie et al. (2018) Functions of the COPII gene paralogs SEC23A and SEC23B are interchangeable in vivo. Proc Natl Acad Sci U S A 115:E7748-E7757
Katz, Steven J; Ward, Kevin C; Hamilton, Ann S et al. (2018) Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol 36:1218-1224
Ulintz, Peter J; Greenson, Joel K; Wu, Rong et al. (2018) Lymph Node Metastases in Colon Cancer Are Polyclonal. Clin Cancer Res 24:2214-2224
Qin, Tingting; Zhang, Yanxiao; Zarins, Katie R et al. (2018) Expressed HNSCC variants by HPV-status in a well-characterized Michigan cohort. Sci Rep 8:11458
Xu, Shilin; Aguilar, Angelo; Xu, Tianfeng et al. (2018) Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. Angew Chem Int Ed Engl 57:1601-1605
Crespo, Joel; Wu, Ke; Li, Wei et al. (2018) Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol 201:814-820
Manohar, Poorni M; Beesley, Lauren J; Bellile, Emily L et al. (2018) Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer. Clin Nucl Med 43:641-647
Hawley, Sarah T; Li, Yun; An, Lawrence C et al. (2018) Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial. J Clin Oncol 36:659-666
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Smith, Joshua; Kulkarni, Aditi; Birkeland, Andrew C et al. (2018) Whole-Exome Sequencing of Sinonasal Small Cell Carcinoma Arising within a Papillary Schneiderian Carcinoma In Situ. Otolaryngol Head Neck Surg 159:859-865

Showing the most recent 10 out of 1493 publications